Forest Laboratories Inc. said Thursday that Canadian regulators approved its high blood pressure drug Bystolic.

Forest said Bystolic will be available in Canada starting in the second quarter. In Forest's latest fiscal quarter, worldwide sales of Bystolic rose 20 percent to $108.8 million.

Shares of Forest rose 45 cents to $37.02 on Thursday, and gave up a penny to $37.01 in aftermarket trading.